RT Journal Article
T1 Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Behçet's Disease: National Multicenter Study of 177 Cases.
A1 Atienza-Mateo, Belén
A1 Martín-Varillas, José Luis
A1 Calvo-Río, Vanesa
A1 Demetrio-Pablo, Rosalía
A1 Beltrán, Emma
A1 Sánchez-Bursón, Juan
A1 Mesquida, Marina
A1 Adan, Alfredo
A1 Hernández, María Victoria
A1 Hernández-Garfella, Marisa
A1 Valls-Pascual, Elia
A1 Martínez-Costa, Lucía
A1 Sellas-Fernández, Agustí
A1 Cordero-Coma, Miguel
A1 Díaz-Llopis, Manuel
A1 Gallego, Roberto
A1 García-Serrano, José L
A1 Ortego-Centeno, Norberto
A1 Herreras, José M
A1 Fonollosa, Alejandro
A1 Garcia-Aparicio, Ángel M
A1 Maíz-Alonso, Olga
A1 Blanco, Ana
A1 Torre-Salaberri, Ignacio
A1 Fernandez-Espartero, Cruz
A1 Jovaní, Vega
A1 Peiteado, Diana
A1 Pato, Esperanza
A1 Cruz, Juan
A1 Férnandez-Cid, Carlos
A1 Aurrecoechea, Elena
A1 García-Arias, Miriam
A1 Castañeda, Santos
A1 Caracuel-Ruiz, Miguel A
A1 Montilla-Morales, Carlos A
A1 Atanes-Sandoval, Antonio
A1 Francisco, Félix
A1 Insua, Santos
A1 González-Suárez, Senen
A1 Sanchez-Andrade, Amalia
A1 Gamero, Fernando
A1 Linares Ferrando, Luis F
A1 Romero-Bueno, F
A1 García-González, A Javier
A1 González, Raquel Almodóvar
A1 Muro, Enrique Minguez
A1 Carrasco-Cubero, Carmen
A1 Olive, Alejandro
A1 Prior, Águeda
A1 Vázquez, Julio
A1 Ruiz-Moreno, Oscar
A1 Jiménez-Zorzo, Fernando
A1 Manero, Javier
A1 Muñoz Fernandez, Santiago
A1 Fernández-Carballido, Cristina
A1 Rubio-Romero, Esteban
A1 Pages, Fred Antón
A1 Toyos-Sáenz de Miera, Francisco J
A1 Martinez, Myriam Gandia
A1 Díaz-Valle, David
A1 López Longo, Francisco J
A1 Nolla, Joan M
A1 Álvarez, Enrique Raya
A1 Martínez, Marcelino Revenga
A1 González-López, Julio José
A1 Rodríguez-Cundin, Paz
A1 Hernández, José L
A1 González-Gay, Miguel A
A1 Blanco, Ricardo
AB To compare the efficacy of infliximab (IFX) versus adalimumab (ADA) as a first-line biologic drug over 1 year of treatment in a large series of patients with refractory uveitis due to Behçet's disease (BD). We conducted an open-label multicenter study of IFX versus ADA for BD-related uveitis refractory to conventional nonbiologic treatment. IFX or ADA was chosen as the first-line biologic agent based on physician and patient agreement. Patients received 3-5 mg/kg intravenous IFX at 0, 2, and 6 weeks and every 4-8 weeks thereafter, or 40 mg subcutaneous ADA every other week without a loading dose. Ocular parameters were compared between the 2 groups. The study included 177 patients (316 affected eyes), of whom 103 received IFX and 74 received ADA. There were no significant baseline differences between treatment groups in main demographic features, previous therapy, or ocular sign severity. After 1 year of therapy, we observed an improvement in all ocular parameters in both groups. However, patients receiving ADA had significantly better outcomes in some parameters, including improvement in anterior chamber inflammation (92.31% versus 78.18% for IFX; P = 0.06), improvement in vitritis (93.33% versus 78.95% for IFX; P = 0.04), and best-corrected visual acuity (mean ± SD 0.81 ± 0.26 versus 0.67 ± 0.34 for IFX; P = 0.001). A nonsignificant difference was seen for macular thickness (mean ± SD 250.62 ± 36.85 for ADA versus 264.89 ± 59.74 for IFX; P = 0.15), and improvement in retinal vasculitis was similar between the 2 groups (95% for ADA versus 97% for IFX; P = 0.28). The drug retention rate was higher in the ADA group (95.24% versus 84.95% for IFX; P = 0.042). Although both IFX and ADA are efficacious in refractory BD-related uveitis, ADA appears to be associated with better outcomes than IFX after 1 year of follow-up.
YR 2019
FD 2019-10-21
LK http://hdl.handle.net/10668/14169
UL http://hdl.handle.net/10668/14169
LA en
DS RISalud
RD Apr 19, 2025